IL227689A0 - The history of aza-indole, their preparation and their use in the treatment of diseases - Google Patents
The history of aza-indole, their preparation and their use in the treatment of diseasesInfo
- Publication number
- IL227689A0 IL227689A0 IL227689A IL22768913A IL227689A0 IL 227689 A0 IL227689 A0 IL 227689A0 IL 227689 A IL227689 A IL 227689A IL 22768913 A IL22768913 A IL 22768913A IL 227689 A0 IL227689 A0 IL 227689A0
- Authority
- IL
- Israel
- Prior art keywords
- prepartion
- aza
- diseases
- treatment
- indole derivatives
- Prior art date
Links
- 125000005334 azaindolyl group Chemical class N1N=C(C2=CC=CC=C12)* 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Virology (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Communicable Diseases (AREA)
- AIDS & HIV (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102011009961A DE102011009961A1 (de) | 2011-02-01 | 2011-02-01 | 7-Azaindolderivate |
| PCT/EP2012/000067 WO2012104007A2 (de) | 2011-02-01 | 2012-01-09 | 7-azaindolderivate |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL227689A0 true IL227689A0 (en) | 2013-11-25 |
Family
ID=45554609
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL227689A IL227689A0 (en) | 2011-02-01 | 2013-07-29 | The history of aza-indole, their preparation and their use in the treatment of diseases |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US8981101B2 (enExample) |
| EP (3) | EP2746281B1 (enExample) |
| JP (1) | JP5891249B2 (enExample) |
| KR (1) | KR20140014158A (enExample) |
| CN (3) | CN103502247B (enExample) |
| AR (1) | AR085110A1 (enExample) |
| AU (1) | AU2012213775B2 (enExample) |
| BR (1) | BR112013019028A2 (enExample) |
| CA (2) | CA2826051C (enExample) |
| DE (1) | DE102011009961A1 (enExample) |
| EA (1) | EA201300873A1 (enExample) |
| ES (3) | ES2861048T3 (enExample) |
| HK (1) | HK1226394A1 (enExample) |
| IL (1) | IL227689A0 (enExample) |
| MX (1) | MX2013008212A (enExample) |
| SG (1) | SG192133A1 (enExample) |
| WO (1) | WO2012104007A2 (enExample) |
| ZA (1) | ZA201306542B (enExample) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102958930B (zh) * | 2010-06-28 | 2018-04-27 | 默克专利有限公司 | 作为用于对抗癌症的激酶抑制剂的2,4-二芳基取代的[1,8]二氮杂萘化合物 |
| DE102010053347A1 (de) * | 2010-12-03 | 2012-06-06 | Merck Patent Gmbh | 3-Hetaryl-substituierte Pyrrolo[2,3-b] pyridin-derivative als PDK1-Inhibitoren |
| DE102011009961A1 (de) * | 2011-02-01 | 2012-08-02 | Merck Patent Gmbh | 7-Azaindolderivate |
| US20150038527A1 (en) * | 2012-02-21 | 2015-02-05 | Merck Patent Gmbh | Furopyridine derivatives |
| DE102012019369A1 (de) | 2012-10-02 | 2014-04-03 | Merck Patent Gmbh | 7-Azaindolderivat |
| FR3001219A1 (fr) * | 2013-01-22 | 2014-07-25 | Centre Nat Rech Scient | Inhibiteurs de kinases |
| GB201303109D0 (en) | 2013-02-21 | 2013-04-10 | Domainex Ltd | Novel pyrimidine compounds |
| US20140303121A1 (en) | 2013-03-15 | 2014-10-09 | Plexxikon Inc. | Heterocyclic compounds and uses thereof |
| NZ630875A (en) * | 2013-03-15 | 2017-12-22 | Plexxikon Inc | Heterocyclic compounds and uses thereof |
| TW201613916A (en) | 2014-06-03 | 2016-04-16 | Gilead Sciences Inc | TANK-binding kinase inhibitor compounds |
| KR101949624B1 (ko) | 2014-09-26 | 2019-02-18 | 길리애드 사이언시즈, 인코포레이티드 | Tank-결합 키나제 억제제 화합물로서 유용한 아미노트리아진 유도체 |
| US10875844B2 (en) | 2015-03-04 | 2020-12-29 | Dana-Farber Cancer Institute, Inc. | Salicylate inhibitors of MELK and methods of use |
| US10160755B2 (en) | 2015-04-08 | 2018-12-25 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
| AU2016287335B2 (en) * | 2015-06-29 | 2020-01-23 | Merck Patent Gmbh | TBK/IKKepsilon inhibitor compounds and uses thereof |
| WO2017106556A1 (en) | 2015-12-17 | 2017-06-22 | Gilead Sciences, Inc. | Tank-binding kinase inhibitor compounds |
| EP3390387B1 (en) | 2015-12-18 | 2021-11-17 | Bayer Pharma Aktiengesellschaft | Heteroarylbenzimidazole compounds |
| CN105906608B (zh) * | 2016-05-03 | 2018-10-19 | 中山大学 | 8-氨基喹啉-松果体素杂联体及其药物组合物 |
| WO2017207534A1 (en) | 2016-06-03 | 2017-12-07 | Bayer Pharma Aktiengesellschaft | Substituted heteroarylbenzimidazole compounds |
| GB201702947D0 (en) | 2017-02-23 | 2017-04-12 | Domainex Ltd | Novel compounds |
| CN110461841B (zh) * | 2017-06-19 | 2020-09-15 | 上海和誉生物医药科技有限公司 | 一种具有csf1r抑制活性的氮杂芳基衍生物、其制备方法和应用 |
| AU2018348241B2 (en) | 2017-10-13 | 2023-01-12 | Opna Bio SA | Solid forms of a compound for modulating kinases |
| CN112839648B (zh) * | 2018-06-07 | 2025-04-04 | 达萨玛治疗公司 | Sarm1抑制剂 |
| ES3028093T3 (en) | 2018-06-07 | 2025-06-18 | Disarm Therapeutics Inc | Inhibitors of sarm1 |
| KR20200046680A (ko) * | 2018-10-25 | 2020-05-07 | 한국과학기술원 | Pdk1 저해제를 포함하는 역노화 유도용 조성물 |
| WO2025016273A1 (zh) * | 2023-07-14 | 2025-01-23 | 拜西欧斯（北京）生物技术有限公司 | 异喹啉衍生物、包含其的药物组合物以及它们的用途 |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5747469A (en) | 1991-03-06 | 1998-05-05 | Board Of Regents, The University Of Texas System | Methods and compositions comprising DNA damaging agents and p53 |
| GB9904387D0 (en) | 1999-02-25 | 1999-04-21 | Pharmacia & Upjohn Spa | Antitumour synergistic composition |
| AU5213300A (en) | 1999-05-19 | 2000-12-12 | Smithkline Beecham Plc | 2-nh-pyridones and pyrimidones as mrs inhibitors |
| WO2005047266A1 (en) * | 2003-11-14 | 2005-05-26 | Lorus Therapeutics Inc. | Aryl imidazoles and their use as anti-cancer agents |
| SE0303180D0 (sv) * | 2003-11-26 | 2003-11-26 | Astrazeneca Ab | Novel compounds |
| UA87494C2 (en) * | 2004-03-30 | 2009-07-27 | Вертекс Фармасьютикалс Инкорпорейтед | Azaindoles useful as inhibitors of jak and other protein kinases |
| CA2560454C (en) | 2004-03-30 | 2013-05-21 | Vertex Pharmaceuticals Incorporated | Azaindoles useful as inhibitors of jak and other protein kinases |
| FR2868422B1 (fr) | 2004-03-31 | 2006-07-14 | Aventis Pharma Sa | Nouveaux derives pyrrolo(2,3-b) pyridine, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases |
| US20080153869A1 (en) * | 2004-06-14 | 2008-06-26 | Bressi Jerome C | Kinase Inhibitors |
| US7709645B2 (en) | 2004-07-27 | 2010-05-04 | Sgx Pharmaceuticals, Inc. | Pyrrolo-pyridine kinase modulators |
| WO2006050076A1 (en) * | 2004-10-29 | 2006-05-11 | Janssen Pharmaceutica, N.V. | Pyrimidinyl substituted fused-pyrrolyl compounds useful in treating kinase disorders |
| WO2006052568A2 (en) | 2004-11-10 | 2006-05-18 | Eli Lilly And Company | Tgf-beta inhibitors |
| EP1828180A4 (en) * | 2004-12-08 | 2010-09-15 | Glaxosmithkline Llc | 1H-pyrrolo [2,3-BETA] PYRIDINE |
| US20090275570A1 (en) | 2005-04-06 | 2009-11-05 | Astrazeneca Ab | Substituted heterocycles and their use as chk1, pdk1 and pak inhibitors |
| WO2006130673A1 (en) * | 2005-05-31 | 2006-12-07 | Janssen Pharmaceutica, N.V. | 3-benzoimidazolyl-pyrazolopyridines useful in treating kinase disorders |
| JP2007099640A (ja) | 2005-09-30 | 2007-04-19 | Tsumura & Co | 含窒素複素環化合物、その製造方法およびそれを用いた医薬組成物 |
| CN101374839A (zh) * | 2006-01-17 | 2009-02-25 | 沃泰克斯药物股份有限公司 | 适用作詹纳斯激酶抑制剂的吖吲哚类 |
| EP2537849A3 (en) * | 2006-01-17 | 2013-04-03 | Vertex Pharmaceuticals, Inc. | Azaindoles useful as inhibitors of janus kinases |
| DE102006012617A1 (de) | 2006-03-20 | 2007-09-27 | Merck Patent Gmbh | 4-(Pyrrolopyridinyl)-pyrimidinyl-2-amin-derivate |
| US20100267707A1 (en) | 2006-06-22 | 2010-10-21 | Merck Sharp & Dohme Corp. | Tyrosine Kinase Inhibitors |
| EP2038272B8 (en) | 2006-06-30 | 2013-10-23 | Sunesis Pharmaceuticals, Inc. | Pyridinonyl pdk1 inhibitors |
| CA2673003A1 (en) | 2006-12-22 | 2008-07-03 | Novartis Ag | Quinazolines for pdk1 inhibition |
| AU2008226844A1 (en) | 2007-03-13 | 2008-09-18 | Merck Sharp & Dohme Corp. | Inhibitors of janus kinases and/or 3-phosphoinositide-dependent protein kinase-1 |
| AU2008266883B2 (en) | 2007-06-20 | 2014-01-30 | Merck Sharp & Dohme Corp. | Inhibitors of janus kinases |
| DE102007028515A1 (de) * | 2007-06-21 | 2008-12-24 | Merck Patent Gmbh | 6-(Pyrrolopyridinyl)-pyrimidinyl-2-amin-derivate |
| WO2009054941A1 (en) | 2007-10-25 | 2009-04-30 | Merck & Co., Inc. | Therapeutic compounds |
| RU2503676C2 (ru) * | 2008-02-25 | 2014-01-10 | Ф.Хоффманн-Ля Рош Аг | Пирролопиразиновые ингибиторы киназы |
| DE102008025751A1 (de) * | 2008-05-29 | 2009-12-03 | Merck Patent Gmbh | 4-(1H-Pyrrolo[2,3-b]pyridin-3-yl)-pyridin-2-ylamin-derivate |
| DE102008031517A1 (de) | 2008-07-03 | 2010-01-07 | Merck Patent Gmbh | Pyrrolopyridinyl-pyrimidin-2-yl-amin-derivate |
| DE102008038221A1 (de) * | 2008-08-18 | 2010-02-25 | Merck Patent Gmbh | 7-Azaindolderivate |
| CN101723936B (zh) | 2008-10-27 | 2014-01-15 | 上海睿星基因技术有限公司 | 激酶抑制剂及其在药学中的用途 |
| DE102009019962A1 (de) | 2009-05-05 | 2010-11-11 | Merck Patent Gmbh | 3-([1,2,3]Triazol-4-yl)-pyrrolo[2,3-b]pyridinderivate |
| WO2011149950A2 (en) * | 2010-05-24 | 2011-12-01 | University Of Rochester | Bicyclic heteroaryl kinase inhibitors and methods of use |
| CN102958930B (zh) * | 2010-06-28 | 2018-04-27 | 默克专利有限公司 | 作为用于对抗癌症的激酶抑制剂的2,4-二芳基取代的[1,8]二氮杂萘化合物 |
| DE102010053347A1 (de) | 2010-12-03 | 2012-06-06 | Merck Patent Gmbh | 3-Hetaryl-substituierte Pyrrolo[2,3-b] pyridin-derivative als PDK1-Inhibitoren |
| DE102011009961A1 (de) * | 2011-02-01 | 2012-08-02 | Merck Patent Gmbh | 7-Azaindolderivate |
-
2011
- 2011-02-01 DE DE102011009961A patent/DE102011009961A1/de not_active Withdrawn
-
2012
- 2012-01-09 ES ES16002047T patent/ES2861048T3/es active Active
- 2012-01-09 AU AU2012213775A patent/AU2012213775B2/en not_active Ceased
- 2012-01-09 US US13/983,083 patent/US8981101B2/en not_active Expired - Fee Related
- 2012-01-09 ES ES12701437.1T patent/ES2608317T3/es active Active
- 2012-01-09 JP JP2013552124A patent/JP5891249B2/ja not_active Expired - Fee Related
- 2012-01-09 WO PCT/EP2012/000067 patent/WO2012104007A2/de not_active Ceased
- 2012-01-09 CA CA2826051A patent/CA2826051C/en not_active Expired - Fee Related
- 2012-01-09 CN CN201280007145.3A patent/CN103502247B/zh not_active Expired - Fee Related
- 2012-01-09 EP EP14000623.0A patent/EP2746281B1/de not_active Not-in-force
- 2012-01-09 BR BR112013019028A patent/BR112013019028A2/pt not_active IP Right Cessation
- 2012-01-09 CA CA3082435A patent/CA3082435A1/en not_active Abandoned
- 2012-01-09 KR KR1020137022887A patent/KR20140014158A/ko not_active Withdrawn
- 2012-01-09 CN CN201610048667.8A patent/CN105732617B/zh not_active Expired - Fee Related
- 2012-01-09 SG SG2013056726A patent/SG192133A1/en unknown
- 2012-01-09 EP EP16002047.5A patent/EP3133074B1/de not_active Not-in-force
- 2012-01-09 EP EP12701437.1A patent/EP2670748B1/de not_active Not-in-force
- 2012-01-09 ES ES14000623.0T patent/ES2634643T3/es active Active
- 2012-01-09 CN CN201610048764.7A patent/CN105712991B/zh not_active Expired - Fee Related
- 2012-01-09 EA EA201300873A patent/EA201300873A1/ru unknown
- 2012-01-09 MX MX2013008212A patent/MX2013008212A/es not_active Application Discontinuation
- 2012-02-01 AR ARP120100332A patent/AR085110A1/es not_active Application Discontinuation
-
2013
- 2013-07-29 IL IL227689A patent/IL227689A0/en active IP Right Grant
- 2013-08-30 ZA ZA2013/06542A patent/ZA201306542B/en unknown
-
2015
- 2015-02-06 US US14/616,113 patent/US9266887B2/en not_active Expired - Fee Related
-
2016
- 2016-01-05 US US14/987,946 patent/US9725446B2/en not_active Expired - Fee Related
- 2016-12-23 HK HK16114637.2A patent/HK1226394A1/zh unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL227689A0 (en) | The history of aza-indole, their preparation and their use in the treatment of diseases | |
| IL232256A0 (en) | Novel purine derivatives and their use in the treatment of disease | |
| IL221874A (en) | History of pyrimidine and their use in the treatment of respiratory diseases such as copd | |
| IL231536A (en) | Indazole-3-carboxamides, pharmaceuticals containing them and their use in the treatment of diseases | |
| AP3807A (en) | Novel heterocyclic derivatives and their use in the treatment of neurological disorders | |
| EP2712378A4 (en) | MEDICAL KIOSK AND METHOD OF USE | |
| ZA201307797B (en) | Bicyclic heterocycle compounds and their uses in therapy | |
| EP2811897A4 (en) | MEDICAL TERMINAL AND APPLICATION METHOD | |
| ZA201306148B (en) | Use of 3-(5-amino-2-methyl-4-oxoquinazolin-3(4h)-yl)piperidine-2-6-dione in treatment of immune-related and inflammatory diseases | |
| IL232229B (en) | Diagnostics accompanying treatment with an anti-hyaluronan factor and methods of using it | |
| ZA201308859B (en) | Quinazolines as therapeutic compounds and related methods of use | |
| IL239557A0 (en) | Microarray for providing therapeutic material and methods for use | |
| PT3604339T (pt) | Anticorpos terapêuticos contra a proteína ror-1 e métodos para utilização dos mesmos | |
| IL221873A (en) | Pyrimidine derivatives and their use in the treatment of respiratory diseases such as copd | |
| GB201120993D0 (en) | Novel compounds and their use in therapy | |
| EP2736533A4 (en) | SELECTIVE DELIVERY MOLECULES AND METHODS OF USE | |
| IL229381B (en) | Brilacitidine and its results for use in the treatment of mucositis | |
| PL2717692T3 (pl) | Kwasy tetrahydrokannabinol-11-owe do stosowania w leczeniu chorób zwłóknieniowych | |
| PL2683826T3 (pl) | Zastosowanie aptamerów w terapii i/lub diagnostyce chorób autoimmunologicznych | |
| EP2709632A4 (en) | COMPOSITIONS AND METHOD FOR THE TREATMENT OF SKIN DISEASES | |
| EP2726079A4 (en) | METHOD OF ADMINISTRATION AND TREATMENT | |
| ZA201401800B (en) | Novel plant defensins and use in the treatment of proliferative diseases | |
| ZA201307058B (en) | Use of polyaminoisoprenyl derrivatives in antobiotic or antisertic treatment | |
| GB2515440B (en) | Vesicular Formulations for use in the treatment of Rosacea | |
| IL231115A0 (en) | Peptides for use in the treatment of diseases and disorders related to - 1 - il |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed |